Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Arteon Inj; TEI 9090; TTC 909

Latest Information Update: 10 Dec 2001

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Teijin Pharma
  • Developer Taisho Pharmaceutical; Teijin Pharma
  • Class Antiplatelets; Antiulcers; Peripheral vasodilators; Prostaglandins; Small molecules; Vascular disorder therapies
  • Mechanism of Action Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Arterial occlusive disorders; Intracranial thrombosis; Ischaemic heart disorders

Most Recent Events

  • 10 Dec 2001 Discontinued-Clinical for Ischaemic heart disorders in Japan (Unknown route)
  • 10 Dec 2001 Discontinued-preregistration for Arterial occlusive disorders in Japan (Injection)
  • 10 Dec 2001 Discontinued-preregistration for Cerebral thrombosis in Japan (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top